DOCSLIB.ORG

Billing and Coding: Removal of Benign Skin Lesions (A57482)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Billing and Coding: Removal of Benign Skin Lesions (A57482) Local Coverage Article: Billing and Coding: Removal of Benign Skin Lesions (A57482) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information CONTRACTOR NAME CONTRACT CONTRACT JURISDICTION STATE(S) TYPE NUMBER Wisconsin Physicians Service Insurance MAC - Part A 05101 - MAC A J - 05 Iowa Corporation Wisconsin Physicians Service Insurance MAC - Part B 05102 - MAC B J - 05 Iowa Corporation Wisconsin Physicians Service Insurance MAC - Part A 05201 - MAC A J - 05 Kansas Corporation Wisconsin Physicians Service Insurance MAC - Part B 05202 - MAC B J - 05 Kansas Corporation Wisconsin Physicians Service Insurance MAC - Part A 05301 - MAC A J - 05 Missouri - Entire Corporation State Wisconsin Physicians Service Insurance MAC - Part B 05302 - MAC B J - 05 Missouri - Entire Corporation State Wisconsin Physicians Service Insurance MAC - Part A 05401 - MAC A J - 05 Nebraska Corporation Wisconsin Physicians Service Insurance MAC - Part B 05402 - MAC B J - 05 Nebraska Corporation Wisconsin Physicians Service Insurance MAC - Part A 05901 - MAC A J - 05 Alabama Corporation Alaska Arizona Arkansas California - Entire State Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Created on 11/15/2019. Page 1 of 14 CONTRACTOR NAME CONTRACT CONTRACT JURISDICTION STATE(S) TYPE NUMBER Louisiana Maine Maryland Massachusetts Michigan Mississippi Missouri - Entire State Montana Nebraska Nevada New Hampshire New Jersey New Mexico North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Wisconsin Physicians Service Insurance MAC - Part A 08101 - MAC A J - 08 Indiana Corporation Wisconsin Physicians Service Insurance MAC - Part B 08102 - MAC B J - 08 Indiana Corporation Wisconsin Physicians Service Insurance MAC - Part A 08201 - MAC A J - 08 Michigan Corporation Wisconsin Physicians Service Insurance MAC - Part B 08202 - MAC B J - 08 Michigan Corporation Created on 11/15/2019. Page 2 of 14 Article Information General Information Article ID Original Effective Date A57482 10/31/2019 Article Title Revision Effective Date Billing and Coding: Removal of Benign Skin Lesions N/A Article Type Revision Ending Date Billing and Coding N/A AMA CPT / ADA CDT / AHA NUBC Copyright Retirement Date Statement N/A CPT codes, descriptions and other data only are copyright 2018 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Current Dental Terminology © 2018 American Dental Association. All rights reserved. Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at [email protected]. Created on 11/15/2019. Page 3 of 14 CMS National Coverage Policy CMS Pub.100-02 Medicare Benefit Policy Manual, Chapter 16 - General Exclusions From Coverage, Section §120 - Cosmetic Surgery CMS Pub. 100-03 Medicare National Coverage Determinations Manual-Chapter 1, Coverage Determinations, Part 4, Section 250.4 - Treatment of Actinic Keratosis CMS Pub.100-04 Medicare Claims Processing Manual, Ch. 23 Fee Schedule Administration and Coding Requirements, Section 10.1-10.1.7 – Reporting ICD Diagnosis and Procedure Codes Title XVIII of the Social Security Act, section 1862 (a)(1)(A). This section allows coverage and payment of those services that are considered to be medically reasonable and necessary. CMS Transmittal No, 857, effective date October 3, 2018 Change Request 10901 Local Coverage Determinations (LCDs) Implementation date January 8, 2019. Article Guidance Article Text: The billing and coding information in this article is dependent on the coverage indications, limitations and/or medical necessity described in the associated LCD L35498 Removal of Benign Skin Lesions. Coding Information 1. Use the CPT code that best describes the procedure, the location and the size of the lesion. If there are multiple lesions treated, multiple codes may be reported but you must follow National Correct Coding Initiative guidelines. CPT code 11200 should be reported with one unit of service. CPT code 11201 should be reported with 1 unit for each additional group of 10 lesions. CPT code 17110 should be reported with one unit of service for removal of benign lesions other than skin tags or cutaneous vascular lesions, up to 14 lesions. CPT code 17111 should be reported with one unit of service for removal of benign lesions other than skin tags or cutaneous vascular lesions, representing 15 or more. CPT codes 11400-11446 should be used when the excision is a full-thickness (through the dermis) removal of a lesion, including margins, and includes simple (non-layered) closure. 2. The provider should use the appropriate CPT code and the diagnosis code should match the CPT code. If a provider bills a benign skin lesion CPT code, it is not correct to use a malignant diagnosis code. 3. If a beneficiary wishes to have one or more benign asymptomatic lesions removed that pose no threat to health or function, and for cosmetic purposes: a. The physician should explain to the patient, in advance, that Medicare will not cover cosmetic cutaneous surgery and that the beneficiary will be liable for the cost of the service. Charges should be clearly stated. A claim for cosmetic services does not need to be submitted to the Medicare Contractor, unless the patient requests that the claim be submitted on his/her behalf. b. When the patient requests the claim for cosmetic services be submitted on his/her behalf, the services should be reported with modifier GY (items or services statutorily excluded or does not meet the definition of any Medicare benefit) and diagnosis code Z41.1. Created on 11/15/2019. Page 4 of 14 4. Evaluation and management services provided on the day, or the day before a dermatological procedure, for the purpose of making the decision to perform the procedure, are not payable. The modifier -57 cannot be used since the decision to perform the dermatological procedure is considered a routine preoperative service and a visit or consultation should not be billed. (Modifier -57 is only applicable for major procedures that have a 90-day global period.) Please refer to Modifier-57 Fact Sheet on WPS GHA website. 5. An E&M service reported on the same day as a dermatological surgery is subject to the Medicare global surgery rules and will only be payable if a significant and separately identifiable medical service is rendered and clearly documented in the patient's medical record. A modifier-25 should be appended to the appropriate visit code to indicate the patient's condition required a significant, separately identifiable visit service in addition to the procedure that was performed. Please refer to Modifier-25 Fact Sheet on WPS GHA website. Removal of benign lesions is elective surgery and generally pre-scheduled. It is inappropriate to report an E&M service with a -25 modifier on the same date of service as these surgeries for the usual pre/post-operative care associated with these surgeries. 6. When billing the destruction of multiple other benign lesions use CPT 17110 or 17111 with a “1” in the unit box. CPT 17110 and CPT 17111 may not be reported together. 7. Medicare will not pay for a separate E/M service on the same day dermatologic surgery is performed unless significant and separately identifiable medical services were rendered and clearly documented in the patient’s medical record. Append modifier 25 to the appropriate visit code to indicate the patient’s condition required a significant, separately identifiable visit service unrelated to the procedure that was performed. Providers should bill the appropriate CPT code and match the diagnosis code to the procedure code. Coding Information CPT/HCPCS Codes Group 1 Paragraph: CPT codes 11300-11313 may also be covered for the removal of cancerous skin lesions which are not addressed in this LCD Group 1 Codes: CODE DESCRIPTION 11200 REMOVAL OF SKIN TAGS, MULTIPLE FIBROCUTANEOUS TAGS, ANY AREA; UP TO AND INCLUDING 15 LESIONS 11201 REMOVAL OF SKIN TAGS, MULTIPLE FIBROCUTANEOUS TAGS, ANY AREA; EACH ADDITIONAL 10 LESIONS, OR PART THEREOF (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE) 11300 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, ARMS OR LEGS; LESION DIAMETER 0.5 CM OR LESS 11301 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, ARMS OR LEGS;
Load more

Recommended publications
  • Extrafacial Granuloma Faciale
    Journal of the American Osteopathic College of Dermatology Volume 11, Number 1 SPONSORS: ',/"!,0!4(/,/'9,!"/2!4/29s-%$)#)3 July 2008 34)%&%,,!"/2!4/2)%3s'!,$%2-! www.aocd.org Journal of the American Osteopathic College of Dermatology Journal of the American Osteopathic College of Dermatology 2007-2008 Officers President: Jay Gottlieb, DO President Elect: Donald Tillman, DO First Vice President: Marc Epstein, DO Second Vice President: Leslie Kramer, DO Third Vice President: Bradley Glick, DO Secretary-Treasurer: Jere Mammino, DO (2007-2010) Immediate Past President: Bill Way, DO Trustees: James Towry, DO (2006-2008) Mark Kuriata, DO (2007-2010) Karen Neubauer, DO (2006-2008) David Grice, DO (2007-2010) Sponsors: Global Pathology Laboratory Editors Stiefel Laboratories Jay S. Gottlieb, D.O., F.O.C.O.O. Medicis Stanley E. Skopit, D.O., F.A.O.C.D. James Q. Del Rosso, D.O., F.A.O.C.D. Galderma Editorial Review Board Ronald Miller, D.O. JAOCD Eugene Conte, D.O. Founding Sponsor Evangelos Poulos, M.D. Stephen Purcell, D.O. Darrel Rigel, M.D. !/#$s%)LLINOISs+IRKSVILLE -/ s&!8 Robert Schwarze, D.O. WWWAOCDORG Andrew Hanly, M.D. #/092)'(4!.$0%2-)33)/.WRITTENPERMISSIONMUSTBEOBTAINED Michael Scott, D.O. FROMTHE*OURNALOFTHE!MERICAN/STEOPATHIC#OLLEGEOF$ERMATOLOGY FORCOPYINGORREPRINTINGTEXTOFMORETHANHALFPAGE TABLESORlGURES Cindy Hoffman, D.O. 0ERMISSIONSARENORMALLYGRANTEDCONTINGENTUPONSIMILARPERMISSION Charles Hughes, D.O. FROMTHEAUTHORS INCLUSIONOFACKNOWLEDGEMENTOFTHEORIGINALSOURCE ANDAPAYMENTOFPERPAGE TABLEORlGUREOFREPRODUCEDMATERIAL Bill Way, D.O. 0ERMISSIONFEESAREWAIVEDFORAUTHORSWISHINGTOREPRODUCETHEIROWN Daniel Hurd, D.O. ARTICLES2EQUESTFORPERMISSIONSHOULDBEDIRECTEDTO*!/#$CO!/#$ 0/"OX+IRKSVILLE -/ Mark Lebwohl, M.D. #OPYRIGHTBYTHE*OURNALOFTHE!MERICAN/STEOPATHIC#OLLEGEOF Edward Yob, D.O. $ERMATOLOGY Jere Mammino, D.O. Printed by: Stoyles Graphics Services, Mason City, IA 50401 Schield M.
    [Show full text]
  • Urticaria from Wikipedia, the Free Encyclopedia Jump To: Navigation, Search "Hives" Redirects Here
    Urticaria From Wikipedia, the free encyclopedia Jump to: navigation, search "Hives" redirects here. For other uses, see Hive. Urticaria Classification and external resourcesICD-10L50.ICD- 9708DiseasesDB13606MedlinePlus000845eMedicineemerg/628 MeSHD014581Urtic aria (or hives) is a skin condition, commonly caused by an allergic reaction, that is characterized by raised red skin wheals (welts). It is also known as nettle rash or uredo. Wheals from urticaria can appear anywhere on the body, including the face, lips, tongue, throat, and ears. The wheals may vary in size from about 5 mm (0.2 inches) in diameter to the size of a dinner plate; they typically itch severely, sting, or burn, and often have a pale border. Urticaria is generally caused by direct contact with an allergenic substance, or an immune response to food or some other allergen, but can also appear for other reasons, notably emotional stress. The rash can be triggered by quite innocent events, such as mere rubbing or exposure to cold. Contents [hide] * 1 Pathophysiology * 2 Differential diagnosis * 3 Types * 4 Related conditions * 5 Treatment and management o 5.1 Histamine antagonists o 5.2 Other o 5.3 Dietary * 6 See also * 7 References * 8 External links [edit] Pathophysiology Allergic urticaria on the shin induced by an antibiotic The skin lesions of urticarial disease are caused by an inflammatory reaction in the skin, causing leakage of capillaries in the dermis, and resulting in an edema which persists until the interstitial fluid is absorbed into the surrounding cells. Urticarial disease is thought to be caused by the release of histamine and other mediators of inflammation (cytokines) from cells in the skin.
    [Show full text]
  • Dermatopathology
    Dermatopathology Clay Cockerell • Martin C. Mihm Jr. • Brian J. Hall Cary Chisholm • Chad Jessup • Margaret Merola With contributions from: Jerad M. Gardner • Talley Whang Dermatopathology Clinicopathological Correlations Clay Cockerell Cary Chisholm Department of Dermatology Department of Pathology and Dermatopathology University of Texas Southwestern Medical Center Central Texas Pathology Laboratory Dallas , TX Waco , TX USA USA Martin C. Mihm Jr. Chad Jessup Department of Dermatology Department of Dermatology Brigham and Women’s Hospital Tufts Medical Center Boston , MA Boston , MA USA USA Brian J. Hall Margaret Merola Department of Dermatology Department of Pathology University of Texas Southwestern Medical Center Brigham and Women’s Hospital Dallas , TX Boston , MA USA USA With contributions from: Jerad M. Gardner Talley Whang Department of Pathology and Dermatology Harvard Vanguard Medical Associates University of Arkansas for Medical Sciences Boston, MA Little Rock, AR USA USA ISBN 978-1-4471-5447-1 ISBN 978-1-4471-5448-8 (eBook) DOI 10.1007/978-1-4471-5448-8 Springer London Heidelberg New York Dordrecht Library of Congress Control Number: 2013956345 © Springer-Verlag London 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
    [Show full text]
  • Basal Cell Carcinoma Associated with Non-Neoplastic Cutaneous Conditions: a Comprehensive Review
    Volume 27 Number 2| February 2021 Dermatology Online Journal || Review 27(2):1 Basal cell carcinoma associated with non-neoplastic cutaneous conditions: a comprehensive review Philip R Cohen MD1,2 Affiliations: 1San Diego Family Dermatology, National City, California, USA, 2Touro University California College of Osteopathic Medicine, Vallejo, California, USA Corresponding Author: Philip R Cohen, 10991 Twinleaf Court, San Diego, CA 92131-3643, Email: [email protected] pathogenesis of BCC is associated with the Abstract hedgehog signaling pathway and mutations in the Basal cell carcinoma (BCC) can be a component of a patched homologue 1 (PCTH-1) transmembrane collision tumor in which the skin cancer is present at tumor-suppressing protein [2-4]. Several potential the same cutaneous site as either a benign tumor or risk factors influence the development of BCC a malignant neoplasm. However, BCC can also concurrently occur at the same skin location as a non- including exposure to ultraviolet radiation, genetic neoplastic cutaneous condition. These include predisposition, genodermatoses, immunosuppression, autoimmune diseases (vitiligo), cutaneous disorders and trauma [5]. (Darier disease), dermal conditions (granuloma Basal cell carcinoma usually presents as an isolated faciale), dermal depositions (amyloid, calcinosis cutis, cutaneous focal mucinosis, osteoma cutis, and tumor on sun-exposed skin [6-9]. However, they can tattoo), dermatitis, miscellaneous conditions occur as collision tumors—referred to as BCC- (rhinophyma, sarcoidal reaction, and varicose veins), associated multiple skin neoplasms at one site scars, surgical sites, systemic diseases (sarcoidosis), (MUSK IN A NEST)—in which either a benign and/or systemic infections (leischmaniasis, leprosy and malignant neoplasm is associated with the BCC at lupus vulgaris), and ulcers.
    [Show full text]
  • Treatment Or Removal of Benign Skin Lesions
    Treatment or Removal of Benign Skin Lesions Date of Origin: 10/26/2016 Last Review Date: 03/24/2021 Effective Date: 04/01/2021 Dates Reviewed: 10/2016, 10/2017, 10/2018, 04/2019, 10/2019, 01/2020, 03/2020, 03/2021 Developed By: Medical Necessity Criteria Committee I. Description Individuals may acquire a multitude of benign skin lesions over the course of a lifetime. Most benign skin lesions are diagnosed on the basis of clinical appearance and history. If the diagnosis of a lesion is uncertain, or if a lesion has exhibited unexpected changes in appearance or symptoms, a diagnostic procedure (eg, biopsy, excision) is indicated to confirm the diagnosis. The treatment of benign skin lesions consists of destruction or removal by any of a wide variety of techniques. The removal of a skin lesion can range from a simple biopsy, scraping or shaving of the lesion, to a radical excision that may heal on its own, be closed with sutures (stitches) or require reconstructive techniques involving skin grafts or flaps. Laser, cautery or liquid nitrogen may also be used to remove benign skin lesions. When it is uncertain as to whether or not a lesion is cancerous, excision and laboratory (microscopic) examination is usually necessary. II. Criteria: CWQI HCS-0184A Note: **If request is for treatment or removal of warts, medical necessity review is not required** A. Moda Health will cover the treatment and removal of 1 or more of the following benign skin lesions: a. Treatment or removal of actinic keratosis (pre-malignant skin lesions due to sun exposure) is considered medically necessary with 1 or more of the following procedures: i.
    [Show full text]
  • Dermatopathology Eva Brehmer-Andersson Dermatopathology
    Eva Brehmer-Andersson Dermatopathology Eva Brehmer-Andersson Dermatopathology With 138 Figures in 445 Separate Illustrations and 5 Tables 123 Eva Brehmer-Andersson Värtavägen 17 115 53 Stockholm Sweden ISBN-10 3-540- 30245-X Springer-Verlag Berlin Heidelberg NewYork ISBN-13 978-3-540- 30245-2 Springer-Verlag Berlin Heidelberg NewYork Library of Congress Control Number: 2006920598 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, speci.cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on micro.lms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law. Springer is a part of Springer Science+Business Media springer.com © Springer-Verlag Berlin Heidelberg 2006 Printed in Germany The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: the publishers cannot guarantee the accuracy of any information about dos- age and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Editor: Gabriele Schröder, Heidelberg Desk Editor: Ellen Blasig, Heidelberg Production and Typesetting: LE-TEX Jelonek, Schmidt & Vöckler GbR, Leipzig Cover Design: Frido Steinen-Broo, EStudio Calamar, Spain Printed on acid-free paper 24/3100/YL 5 4 3 2 1 0 Preface The purpose of this book is to introduce future pathologists and dermatolo- gists to the exciting field of dermatopathology.
    [Show full text]
  • P1448 Paper Poster Session Lyme Disease Borrelia Burgdorferi
    P1448 Paper Poster Session Lyme disease Borrelia burgdorferi seropositivity in various cutaneous disorders Ayse Demet Kaya*1, Ali Haydar Parlak2, Aydın Aydınlı3 1Okan University Medical Faculty,Department of Medical Microbiology, Istanbul, Turkey 2Abant İzzet Baysal University Medical Faculty, Department of Dermatology, Bolu, Turkey 3Okan University Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey Background: Lyme disease, which is caused by the tick-borne spirochete Borrelia burgdorferi, is an important cause of infection in many areas of the world. Majority of lyme borreliosis cases display cutaneous manifestations; including erythema migrans, borrelial lymphocytoma and acrodermatitis chronica atrophicans. In light of the increasing number of reports describing an association between other cutaneous disorders and Borrelia burgdorferi, this study was planned to investigate the role of Borrelia burgdorferi in the etiology of several dermatosis. Material/methods: 161 patients with pitriasis rosea, chronic urticaria, mycosis fungoides, granuloma annulare, linear scleroderma, erythema annulare, keloid morphea, pseudolymphoma, pityriasis lichenoides chronica, pityriasis lichenoides et varioliformis acuta, lichen sclerosus, morphea, granuloma faciale were initially underwent physical examination and blood samples of were obtained to determine the presence of IgM and IgG antibodies. A two-step testing strategy was used. The sera were initially tested by enzyme-linked immunosorbent assay(ELISA) and then by Western blot(WB). Demographic data regarding residence, age, sex, profession, tick-bite history, contact with animals, and symptoms concerning skin, nervous system and osteoarticular system were collected using a questionnaire and all results were statistically evaluated by x² test. Results: Of 161 sera of patients with dermatosis, Borrelia IgG and IgM positivities were 20 (12.4%) and 4 (2.5%), respectively.
    [Show full text]
  • A Deep Learning System for Differential Diagnosis of Skin Diseases
    A deep learning system for differential diagnosis of skin diseases 1 1 1 1 1 1,2 † Yuan Liu ,​ Ayush Jain ,​ Clara Eng ,​ David H. Way ,​ Kang Lee ,​ Peggy Bui ,​ Kimberly Kanada ,​ ​ ​ ‡ ​ 1​ ​ 1 ​ 1 ​ Guilherme de Oliveira Marinho ,​ Jessica Gallegos ,​ Sara Gabriele ,​ Vishakha Gupta ,​ Nalini 1,3,§ 1 ​ ​ 4 ​ 1 ​ ​ 1 Singh ,​ Vivek Natarajan ,​ Rainer Hofmann-Wellenhof ,​ Greg S. Corrado ,​ Lily H. Peng ,​ Dale ​ ​ 1 1 ​ † 1, ​ 1, ​ 1, ​ R. Webster ,​ Dennis Ai ,​ Susan Huang ,​ Yun Liu *​ , R. Carter Dunn *​ *, David Coz *​ * ​ ​ ​ ​ ​ ​ Affiliations: 1 G​ oogle Health, Palo Alto, CA, USA 2 U​ niversity of California, San Francisco, CA, USA 3 M​ assachusetts Institute of Technology, Cambridge, MA, USA 4 M​ edical University of Graz, Graz, Austria † W​ ork done at Google Health via Advanced Clinical. ‡ W​ ork done at Google Health via Adecco Staffing. § W​ ork done at Google Health. *Corresponding author: [email protected] **These authors contributed equally to this work. Abstract Skin and subcutaneous conditions affect an estimated 1.9 billion people at any given time and remain the fourth leading cause of non-fatal disease burden worldwide. Access to dermatology care is limited due to a shortage of dermatologists, causing long wait times and leading patients to seek dermatologic care from general practitioners. However, the diagnostic accuracy of general practitioners has been reported to be only 0.24-0.70 (compared to 0.77-0.96 for dermatologists), resulting in over- and ​ ​ ​ ​ ​ ​ ​ under-referrals, delays in care, and errors in diagnosis and treatment. In this paper, we developed a deep learning system (DLS) to provide a differential diagnosis of skin conditions for clinical cases (skin photographs and associated medical histories).
    [Show full text]
  • 86A1bedb377096cf412d7e5f593
    Contents Gray..................................................................................... Section: Introduction and Diagnosis 1 Introduction to Skin Biology ̈ 1 2 Dermatologic Diagnosis ̈ 16 3 Other Diagnostic Methods ̈ 39 .....................................................................................Blue Section: Dermatologic Diseases 4 Viral Diseases ̈ 53 5 Bacterial Diseases ̈ 73 6 Fungal Diseases ̈ 106 7 Other Infectious Diseases ̈ 122 8 Sexually Transmitted Diseases ̈ 134 9 HIV Infection and AIDS ̈ 155 10 Allergic Diseases ̈ 166 11 Drug Reactions ̈ 179 12 Dermatitis ̈ 190 13 Collagen–Vascular Disorders ̈ 203 14 Autoimmune Bullous Diseases ̈ 229 15 Purpura and Vasculitis ̈ 245 16 Papulosquamous Disorders ̈ 262 17 Granulomatous and Necrobiotic Disorders ̈ 290 18 Dermatoses Caused by Physical and Chemical Agents ̈ 295 19 Metabolic Diseases ̈ 310 20 Pruritus and Prurigo ̈ 328 21 Genodermatoses ̈ 332 22 Disorders of Pigmentation ̈ 371 23 Melanocytic Tumors ̈ 384 24 Cysts and Epidermal Tumors ̈ 407 25 Adnexal Tumors ̈ 424 26 Soft Tissue Tumors ̈ 438 27 Other Cutaneous Tumors ̈ 465 28 Cutaneous Lymphomas and Leukemia ̈ 471 29 Paraneoplastic Disorders ̈ 485 30 Diseases of the Lips and Oral Mucosa ̈ 489 31 Diseases of the Hairs and Scalp ̈ 495 32 Diseases of the Nails ̈ 518 33 Disorders of Sweat Glands ̈ 528 34 Diseases of Sebaceous Glands ̈ 530 35 Diseases of Subcutaneous Fat ̈ 538 36 Anogenital Diseases ̈ 543 37 Phlebology ̈ 552 38 Occupational Dermatoses ̈ 565 39 Skin Diseases in Different Age Groups ̈ 569 40 Psychodermatology
    [Show full text]
  • 100 CASES in Dermatology This Page Intentionally Left Blank 100 CASES in Dermatology
    100 CASES in Dermatology This page intentionally left blank 100 CASES in Dermatology Rachael Morris-Jones PhD PCME FRCP Consultant Dermatologist & Honorary Senior Lecturer, King’s College Hospital, London, UK Ann-Marie Powell Consultant Dermatologist, Department of Dermatology, St Thomas’ Hospital, London, UK Emma Benton MB ChB MRCP Post-CCT Clinical Research Fellow, St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Trust, London, UK 100 Cases Series Editor: Professor P John Rees MD FRCP Dean of Medical Undergraduate Education, King’s College London School of Medicine at Guy’s, King’s and St Thomas’ Hospitals, London, UK First published in Great Britain in 2011 by Hodder Arnold, an imprint of Hodder Education, a division of Hachette UK 338 Euston Road, London NW1 3BH http://www.hodderarnold.com © 2011 Rachael Morris-Jones, Ann-Marie Powell and Emma Benton All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency. In the United Kingdom such licences are issued by the Copyright Licensing Agency: Saffron House, 6–10 Kirby Street, London EC1N 8TS Hachette UK’s policy is to use papers that are natural, renewable and recyclable products and made from wood grown in sustainable forests. The logging and manufacturing processes are expected to conform to the environmental regulations of the country of origin.
    [Show full text]
  • Laser Therapy for the Treatment of Morphea: a Systematic Review of Literature
    Journal of Clinical Medicine Review Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature Paulina Szczepanik-Kułak * , Małgorzata Michalska-Jakubus and Dorota Krasowska Chair and Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland; [email protected] (M.M.-J.); [email protected] (D.K.) * Correspondence: [email protected] Abstract: Morphea, also known as localized scleroderma (LoS), comprises a set of autoimmune sclerotic skin diseases. It is characterized by inflammation and limited thickening and induration of the skin; however, in some cases, deeper tissues might also be involved. Although morphea is not considered a life-threatening disease, the apparent cosmetic disfigurement, functional or psychosocial impairment affects multiple fields of patients’ quality of life. Therapy for LoS is often unsatisfactory with numerous treatments that have only limited effectiveness or considerable side effects. Due to the advances in the application of lasers and their possible beneficial effects, the aim of this study is to review the reported usage of laser in morphea. We present a systematic review of available literature, performed with MEDLINE, Cinahl, Central, Scopus, Web of Science, and Google Scholar databases. We identified a total of twenty relevant studies (MEDLINE n = 10, Cinahl n = 1, Central n = 0, Scopus n = 2, Web of Science n = 5, Google Scholar n = 2) using laser therapy for LoS. Eight studies were focused on the use of PDL, six on fractional lasers (CO2 and Er:YAG), four on excimer, and two on either alexandrite or Nd:YAG. Keywords: morphea; localized scleroderma; laser therapy Citation: Szczepanik-Kułak, P.; Michalska-Jakubus, M.; Krasowska, D.
    [Show full text]
  • Copyrighted Material
    Index Note: Page numbers in italics refer to Figures. anaplastic large cell lymphoma primary cutaneous, 155 A systemic, 155 abscess, 164 androgenetic alopecia, 341, 344 acantholysis, 59, 60 annular elastolytic giant cell granuloma, 190–191 acanthosis, 5, 7, 20, 27, 30, 37, 46, 55, 56, 66, 213 argyria, 288 acanthosis nigricans, 13 Arndt-Gottron, 299 acne agminata, 184 arteriosclerosis, 263 acne comedonica, 323 arthropod bite reaction, 44–5, 129, 141, 168 acne cystica, 323 atopic dermatitis, 2, 36–7 acneiform reaction, 336 chronic, 57 acne pustulosa, 324 atrophie blanche (capillaritis alba), 228–30 acne vulgaris, 322, 338 axillary perifollicular xanthomatosis, 294 acne comedonica, 323 acne cystica, 323 B acne pustulosa, 324 bacterial folliculitis, 336 bacterial folliculitis, 336 Behçet’s disease, 254 demodex folliculitis, 334 Bizarre anemic spots, 227 eosinophilic folliculitis and papular eruption black patch/nodule, 287 of HIV, 337 blisters granulomatous rosacea, 329–30 cheiropomphylox or pomphylox, 18 perioral dermatitis, 332 erythema, 19 pityrosporum folliculitis, 335 papillomatous growth and vegetations, 61 rhinophyma, 333 subepidermal, 131 rosacea, 325–6 suprabasal acantholytic, 62 rosacea conglobata, 331 blue nevus, 287 rosacea fulminans, 327 bowenoid papulosis, 97–8 rosacea, persistent edema (Morbihan), 328 bullous, 237 acrodermatitis bullous epidermolytic ichthyosis, 6, 10–11 chronica atrophicans, 107 bullous pemphigoid, 24, 68, 122–4, 166 enteropathica (zinc deficiency-syndrome), 86 arthropod bite reaction, 141 papular acrodermatitis
    [Show full text]